24.10.2005 – 09:07

Intercell AG

euro adhoc: Intercell AG
Board of Directors (Appointments and Changes) / Intercell appoints Management Board for further growth - Gerd Zettlmeissl - new CEO, Alexander von Gabain - new CSO, Werner Lanthaler - CFO

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.

24.10.2005

Intercell AG (VSE, "ICLL") today announced that the company's
Supervisory Board has appointed its management board with new
responsibilities for the next three years. This appointment
guarantees the optimal use of individual strength, know how and
industrial experience of its members for the next stage of the
company’s growth. The commercialization of Intercell’s own products,
the successful partnering of its outstanding technologies and ongoing
progress in its scientific and development work are now crucial for
the further growth and strategic positing of the company with in the
vaccine industry. The members of the new management board are Gerd
Zettlmeissl (Chief Executive Officer), Alexander von Gabain (Chief
Scientific Officer) and Werner Lanthaler (Chief Financial Officer).

"I am impressed by the achievements of Alexander von Gabain and his
team. They managed to build up a world wide acknowledged vaccine
company with late stage products and outstanding technologies in less
than seven years. Under the new leadership of Gerd Zettlmeissl the
company is now optimally prepared to master its upcoming challenges
and periods of future growth", states Ernst Guenther Afting, Chairman
of Intercell’s Supervisory Board.

Alexander von Gabain states: "The new definition of roles within our
excellent team will enable us to use our individual strengths even
better. As the company moves further downstream it was my own desire
to free up again more time for our breakthrough technologies and our
Business Development activities and thereby serve the future of
Intercell in the very best fashion."

Gerd Zettlmeissl states: "It is a great honor to lead the company now
as CEO. I take over a vaccine company with clinical programs,
technologies and an organization, which are all in best shape. This
will enable to create even more value for Intercell in the future."

Before joining Intercell as Chief Operating Officer in 2001 the
future Chief Executive Officer, Gerd Zettlmeissl, served as CEO of
Chiron’s fully integrated German vaccine subsidiary Chiron Behring.
Having worked in the pharmaceutical industry for more than 20 years,
Gerd Zettlmeissl has considerable experience in the discovery,
development, manufacturing and commercialization of biotech products
like e.g. novel vaccines against influenza and meningococcal
infections.

Intercell’s founding CEO, Alexander von Gabain, will commit himself
in his new position as Chief Scientific Officer to the company’s
research and to creating new business from Intercell’s outstanding
R&D and technology platforms. Before founding Intercell, Alexander
von Gabain served as Chairman of the Department of Microbiology and
Genetics at the University of Vienna and as Professor at the
Karolinska Institute, Stockholm, Sweden.

Chief Financial Officer, Werner Lanthaler, will assume additional
responsibilities for Intercell’s Marketing and Sales Activities to
ensure a successful global launch of the company’s Japanese
Encephalitis vaccine planned for 2007.  Before joining Intercell in
2001, Werner Lanthaler was Head of Marketing and Communication of the
Austrian Federation of Industry and Senior Consultant at McKinsey &
Company.

Michael Buschle will no longer be part of the Management Board of
Intercell AG. He will continue his responsibility as General Manager
of Intercell´s manufacturing subsidiary in Livingston, Scotland.

About Intercell  Intercell AG is a fast growing biotechnology company
with a clear strategy and focus on the design and development of
novel vaccines for prevention and treatment of infectious diseases
with substantial unaddressed medical need. The Company’s unique
position is based on the combination of antigens and immunizers
(adjuvants) derived from its proprietary technology platforms and its
in-house GMP manufacturing facilities. Intercell’s technology has
been endorsed by collaborative agreements with a number of global
pharmaceutical companies, including sanofi pasteur, Merck&Co., Inc.,
SciGen Ltd. and the Statens Serum Institut. The Company has a broad
development pipeline with a vaccine for Japanese Encephalitis
undergoing Phase III clinical trials, a vaccine for Hepatitis C in
Phase II trials, and five products focused on infectious diseases in
the pre-clinical phase. Intercell is listed on the Vienna stock
exchange under the symbol "ICLL".

This communication expressly or implicitly contains certain
forward-looking statements concerning Intercell AG and its business.
Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Intercell AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Intercell AG is providing this communication as of this date and does
not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.

end of announcement                               euro adhoc 24.10.2005 08:29:43

Further inquiry note:

Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN:
Börsen: Wiener Börse AG / official market